But not as first line therapy alas, though some haematologists may perhaps work around these conditions. Venetoclax + Rituximab is already fully funded here
""Ibrutinib to be funded in New Zealand
People with chronic lymphocytic leukaemia (CLL) and certain clinical circumstances will have access to funded ibrutinib (Imbruvica) from 1 December 2022. This will mean funded access for people:
• whose disease progresses during treatment with venetoclax
• whose disease relapses within 3 years of treatment with venetoclax
• for whom venetoclax results in intolerable side effects
We estimate that in the first year approximately 30 people will be eligible for funding. We expect that this will increase with each year of funding. After five years over 100 people will be eligible for treatment with ibrutinib each year. ""
Written by
morepork
To view profiles and participate in discussions please or .
I saw this update and personally I think Pharmac is a joke and likes to dangle a carrot. This is not funded in Nz as first line treatment as myself and many others have to self fund Ibrutinib. Nz is one of the wealthiest countries in the world and Pharmac still refuses to find drugs that have been funded in every other country. No wonder most Nz go to Australia or Uk to get treatment. Nz is not a good place to be if you need the best treatment the health system is broken. Thankyou Andrew Little.
The clinicaltrials.gov website lists some trial sites in New Zealand for a trial of a new BCL-2 inhibitor (BGB-11417). It was recently discussed in this post:
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.